This Project Grant awarded by the National Cancer Institute (NCI), under the federal Cancer Treatment Research program (CFDA 93.395), provides $1,022,522 to Isoprene Pharmaceuticals Inc. to develop their lead compound VNPP433-3B as a novel oral therapeutic for treating both primary and metastatic prostate cancer. The key objectives are to: 1) Synthesize 500g of non-GMP VNPP433-3B for preclinical studies, 2) Conduct additional pharmacology testing of VNPP433-3B using in vitro and in vivo prostate...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...
The National Cancer Institute (NCI), under the federal Cancer Treatment Research program (CFDA 93.395), awarded a $999,960 Project Grant to Linnaeus Therapeutics Inc. on January 13, 2025. The purpose of this grant is to expand upon preliminary clinical data and complete a proof-of-concept study of the drug candidate LNS8801 for treating melanoma patients who cannot tolerate immunotherapy due to immune-related adverse events. LNS8801 is an orally deliverable small molecule that targets the G...
This $692,072 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will fund the development of a novel theranostic platform using PSMA-targeted poly(amidoamine) (PAMAM) dendrimers for the management of prostate cancer. The key products to be delivered include: PSMA-targeted theranostic agents that enable highly specific targeting, quantitative PET/CT imaging for patient selection, and delivery of potent antimitotic agents....
The National Cancer Institute awarded a $1,078,680 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Nerx Biosciences Inc., a small disadvantaged business located in Indianapolis, Indiana. The goal of this 2-year award, effective August 1, 2024, is to accelerate the commercial readiness of NERX-329, a novel small molecule inhibitor that disrupts the DNA damage response (DDR) sensor replication protein A (RPA). This inhibitor represents a first-in-class approach to targeting the DDR...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $399,491 to Northridge Tri-Modality Imaging Inc. to upgrade their gantry-based imaging system to incorporate bioluminescence tomography (BLT) capabilities. The upgraded system will enable 3D whole-body fluorescent, bioluminescent, and anatomical X-ray imaging of small animal cancer models, providing a comprehensive multimodal imaging...
The National Cancer Institute (NCI) awarded a $399,214 Project Grant under CFDA 93.395 - Cancer Treatment Research to Proton Bio, Inc., a minority-owned business located in Baltimore, Maryland. The grant supports a 12-month project to develop and evaluate a novel therapy targeting the proton-sensing receptor GPR68 as a potential treatment for glioblastoma (GBM), the most common and aggressive form of adult brain cancer. The project will focus on three key objectives: 1) define the in vitro...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $792,367 to Nanopharmaceuticals LLC to develop a novel dual-targeting ligand, NP855, for the treatment of high-risk neuroblastoma. The key products and services to be delivered under this grant include: Scaled-up manufacturing and analytical evaluation of the NP855 drug substance to enable formulation of the drug product. In vitro and in vivo studies to confirm the efficacy of the...
This federal Project Grant award of $644,622 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to enhance radioligand therapy for prostate cancer through the development of biomarker and dosimetry-guided personalized treatment approaches. The key objectives are to: 1) develop a novel method for bone marrow dosimetry using macro/micro Monte Carlo modeling, 2) build predictive models to estimate absorbed radiation doses from pre-therapy PET...
The National Cancer Institute (NCI) awarded a $185,760 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Regents of the University of California, San Francisco (UCSF) to develop a novel tumor-targeted combination therapy for metastatic castration-resistant prostate cancer (mCRPC). The project aims to enhance efficacy and reduce toxicity by co-delivering cytotoxic drugs and the radioactive isotope Actinium-225 directly to cancer cells. Key objectives include developing...
This Project Grant award from the National Cancer Institute (CFDA 93.394, Cancer Detection and Diagnosis Research) provides $1,811,052.00 to Manzanita Pharmaceuticals Inc. to conduct IND-enabling toxicology and safety studies for "Nervelight", a novel nerve imaging agent for use during prostate cancer radical prostatectomy procedures. The key products to be delivered under this 2-year project include: 1) non-GLP dose-range finding studies in dogs to determine the optimal dose and confirm the agent's localization in target nerves, and 2) GLP toxicology and safety pharmacology studies in rats and dogs to confirm the safety profile of Nervelight per FDA guidance. Upon successful completion of these IND-enabling studies, the awardee plans to initiate a Phase 1 clinical trial to test Nervelight in men undergoing radical prostatectomies.